News from pharmamar A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

19 May, 2016, 09:00 BST PharmaMar Announces New Data on Yondelis®, Aplidin® and PM1183 to be Presented at 2016 ASCO Annual Meeting

Results from a Phase I study of Aplidin® (plitidepsin) in combination with bortezomib and dexamethasone in patients with multiple myeloma will be...


19 May, 2016, 09:00 BST PharmaMar Reports Positive Results from the Phase I Study of Aplidin® (plitidepsin) in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting

The data will be presented in an oral session (abstract #8006) The conclusions of the study point to a response rate of 56% of the treated patients...


19 May, 2016, 09:00 BST PharmaMar Announces New Advances in Their Compounds Yondelis®, plitidepsin and lurbinectedin at ASCO 2016

During this event, where more than 30.000 oncologists from around the world will meet, various studies relating to the three compounds of marine...


14 Apr, 2016, 09:00 BST PharmaMar Will be Present at the 2016 Annual AACR Congress with the Latest Novelties in its Compounds of Marine Origin in Solid and Hematological Tumors

PharmaMar (MSE:PHM) will present the latest data obtained on its compounds of marine origin, lurbinectedin, plitidepsin and PM184 at the Annual...


01 Apr, 2016, 06:30 BST Aplidin® Shows Positive Results in Pivotal Phase III Clinical Trial for Multiple Myeloma

- PharmaMar intends to submit a Marketing Authorization Application to the European Medicines Agency during the last quarter of this year PharmaMar...


11 Mar, 2016, 11:30 GMT Creating a Network of Centres of Reference and Fostering Research to Improve the Prognosis of Sarcoma

Soft Tissue Sarcoma: Evidence and Experience, organised by PharmaMar, will bring together leading international experts in soft tissue sarcoma to...


03 Mar, 2016, 11:30 GMT Yondelis® Approved for Sale in 6 Additional Countries

The regulatory authorities in 6 countries have granted 10 sales authorisations for Yondelis® Five of those authorisations are for Yondelis® in...


26 Feb, 2016, 09:30 GMT PharmaMar Initiates a Phase II Trial With Antitumour Drug PM184 in Advanced Breast Cancer

PharmaMar (MSE:PHM) has announced the start of an open-label multi-centre two-stage Phase II trial with the anti-tumour drug PM184. The trial will be ...


08 Feb, 2016, 09:30 GMT The Phase III Clinical Trial Using PM1183 in Treating Ovarian Cancer (CORAIL) Continues Following the IDMC's Positive Recommendation

PharmaMar (MSE:PHM) has today announced that the Independent Data Monitoring Committee (IDMC) has notified the company that they recommend...


19 Nov, 2015, 11:09 GMT PharmaMar Establishes Subsidiary in Belgium

PharmaMar (MSE:PHM) has announced the opening of a new subsidiary in Brussels (Belgium) to strengthen the commercial team operating in the Benelux...


23 Oct, 2015, 16:30 BST U.S. FDA Approves YONDELIS® (trabectedin) for the Treatment of Liposarcoma or Leiomyosarcoma - Two Common Subtypes of Soft Tissue Sarcoma

PharmaMar announced today that its licensing partner, Janssen Biotech, Inc. received marketing approval for YONDELIS®(trabectedin) by the U.S. Food...


03 Feb, 2015, 08:30 GMT U.S. FDA Grants Priority Review to YONDELIS® NDA for Advanced Soft-tissue Sarcoma

PharmaMar announces that the U.S. Food and Drug Administration (FDA) has granted priority review to YONDELIS® (trabectedin) New Drug Application...


08 Feb, 2011, 00:09 GMT PharmaMar Commences Clinical Trial in U.S. with New Antitumor Product, PM060184

- PM060184 is a new marine-derived compound which has shown strong antitumor activity in preclinical models and a favorable safety profile in animal...